

HepaGam B

STN: BL 125035

Proper Name: Hepatitis B Immune Globulin Intravenous (Human)

Tradename: HepaGam B

Manufacturer: Cangene Corp, License #1201

Indications:

- For the prevention of Hepatitis B recurrence following liver transplantation in HBsAg-positive liver transplant patients. Also indicated for the treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection.
- Treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection.

Product Information

- Package Insert - HepaGam B (</media/74701/download>)

Supporting Documents

- Supporting Documents older than three years-HepaGam B (<https://wayback.archive-it.org/7993/20170404205345/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/>
[🔗](http://www.fda.gov/about-fda/website-policies/website-disclaimer) (<http://www.fda.gov/about-fda/website-policies/website-disclaimer>)